Alzheimer’s Research UK open applications for Research Fellowship grants 

Dementia Carers Count (DCC) has published a briefing and recommendations that they’ve shared with the Casey Commission.  The briefing and recommendations have been informed by what unpaid/family dementia carers have told DCC would make the most difference to their ability to cope and their capacity to care.  Read the briefing and recommendations here: https://dementiacarers.org.uk/content/uploads/2025/07/What-if.-This-could-be-dementia-care-DCC-briefing-to-the-Casey-Commission.pdf  The…

Retired university professor Rex Last is offering a free download of his book “The informal Dementia Carer – who cares?” which is described as a “hard-hitting defence” of the informal carer. Professor Last’s wife, who died in July, was diagnosed with Parkinson’s which developed into dementia.  He says the book is a plea from a…

The Dementia Frontiers Fund has been launched by Alzheimer’s Research UK (ARUK) and Gates Ventures, in collaboration with the Robertson Foundation and Alzheimer’s Disease Data Initiative, with support from the Q Charitable Trust.  Described as, “A bold new multi-million-pound global initiative designed to address the most complex and urgent questions holding back progress in dementia…

Researchers at King’s College London Impact Centre for Palliative and End of Life Care are looking for palliative and end of life care professionals to complete their Stakeholder Survey.  The researchers say:  “Too many people die without the care they need and could benefit from. We have evidence of what works, but too often this…

Tributes to the Queen: Residents of Royal Star & Garter care homes in Solihull, Surbiton and High Wycombe came together on video (see picture) and shared their reflections on the late monarch.  Armed forces veterans and their partners paid tribute to the Queen, who became the charity’s patron in 1953, for her lifetime of service. …

New results from the final stage of extensive clinical trials for the anti-amyloid immunotherapy drug “donanemab” have confirmed significant benefits for people in the early stage of Alzheimer’s disease. The drug, which was shown to slow cognitive and functional decline by 22%, could receive regulatory approval for use in the USA by the end of…